Healthcare
Sernova Corp.(SEOVF)
Live Price
Offline$0.11
-15.38% today
1Y Change
-8.33%
Window
Jun 23, 2025 โ Jun 18, 2026
- Market Cap
- $60.00M
- Revenue Growth
- 0.0%
- EPS Growth
- +52.1%
- Dividend Yield
- 0.0%
Coverage: 249 bars ยท Jun 23, 2025 โ Jun 18, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Sernova Corp. (SEOVF) is a Healthcare stock with a market cap of $60.00M and listed on OTC. The stock last traded around $0.11 and down 8.3% across the available one-year price window (Jun 23, 2025 โ Jun 18, 2026). Baseline metrics include revenue growth of 0.0%, EPS growth of +52.1%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS +52.1%, free cash flow +42.3% with operating margin 0.0% and ROIC 152.4%. Stock Foundry combines SEOVF price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
0.0% vs +7.6% peer median
Operating Margin
Below sector median
0.0% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on Jun 11, 2026, but the surprise data is still limited.
The setup is mixed rather than one-directional
Revenue is 0.0% and EPS is +52.1%, while operating margin sits near 0.0%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged -2.8% over the next 5 trading days and finished higher after 0 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 Jun 11, 2026 | โ | +0.0% | +0.0% | โ |
2026 Mar 13, 2026 | -36.2% | +0.0% | -8.3% | +8.3% |
2025 Dec 19, 2025 | -40.3% | +11.1% | +0.0% | +33.3% |
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
SEOVF
โ
Normalized return
SPY
โ
S&P 500
Excess Return
โ
Relative to SPY
SEOVF Max Drawdown
-43.75%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for SEOVF and SPY.
Company Overview
Sernova Corp.
Other OTC
Sernova Corp. operates as a clinical-stage regenerative medicine therapeutics company in Canada. The company focuses on the development and commercialization of regenerative medicine therapeutics, including its proprietary Cell Pouch and associated technologies consisting of therapeutic cells and local cellular immune protection. Its Cell Pouch is a medical device designed to create a vascularized tissue environment for the transplantation and engraftment of therapeutic cells, which then release proteins and/or hormones for the long-term treatment of various serious chronic diseases, such as diabetes, hemophilia, and thyroid disease. Sernova Corp. has a research collaboration with AgeX Therapeutics, Inc. to generate immune-protected therapeutic cells; and a research agreement with the University of Miami to advance the development of Cell Pouch cell therapy platform. The company was incorporated in 1998 and is headquartered in London, Canada.
- Leadership
- Jonathan N. Rigby
- IPO Date
- Feb 21, 2007
- Employees
- 17
- Street Address
- The Stiller Centre
- Mailing
- London, ON, N6G 4X8
- Region
- London, ON, GB
- Reporting Currency
- USD
- Investor Line
- 519 858 5184
- Last Updated
- May 4, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- โ
- Price/Sales
- โ
- Price/Book
- โ
Growth
- Revenue
- 0.0%
- EPS
- +52.1%
- Free Cash Flow
- +42.3%
Profitability
- Gross Margin
- 0.0%
- Operating Margin
- 0.0%
- Net Margin
- 0.0%
- ROE
- 51.7%
- ROIC
- 152.4%
Balance Sheet
- Debt/Equity
- โ
- Current Ratio
- 0.03
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.